menu search

Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)

– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...

June 3, 2023, 6:15 pm

Cogent biosciences: bezuclastinib's potential in treating gastrointestinal stromal tumors

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointesti...

February 28, 2023, 2:17 am

Cogent biosciences: multiple inflection points for fy23, hold for now

Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of p...

December 27, 2022, 7:02 pm

Cogent biosciences announces positive updated clinical data from ongoing phase 2 apex trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (advsm)

– 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up – Rapid and deep responses seen includin...

December 11, 2022, 10:30 pm

Cogent biosciences to host investor webcast to discuss updated clinical data at ash from the ongoing phase 2 apex trial of bezuclastinib in patients with advanced systemic mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on dev...

December 5, 2022, 8:00 am


Search within

Pages Search Results: